FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569087857> ?p ?o ?g. }

• W1569087857 endingPage "5" @default.
• W1569087857 startingPage "1" @default.
• W1569087857 abstract "Objective . Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods . Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results . Eight males and two females (median age, 67 years (range, 52–78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>7</mml:mn></mml:math>, 70%), cisplatin plus etoposide (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:math>, 20%), and carboplatin plus etoposide (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math>, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion . Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC." @default.
• W1569087857 created "2016-06-24" @default.
• W1569087857 creator A5013179673 @default.
• W1569087857 creator A5014047853 @default.
• W1569087857 creator A5015023308 @default.
• W1569087857 creator A5021776984 @default.
• W1569087857 creator A5032787627 @default.
• W1569087857 creator A5042401726 @default.
• W1569087857 creator A5045136564 @default.
• W1569087857 creator A5056456991 @default.
• W1569087857 creator A5065692477 @default.
• W1569087857 creator A5076120991 @default.
• W1569087857 creator A5078407139 @default.
• W1569087857 creator A5083668667 @default.
• W1569087857 creator A5087388222 @default.
• W1569087857 date "2015-01-01" @default.
• W1569087857 modified "2023-09-27" @default.
• W1569087857 title "Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma" @default.
• W1569087857 cites W1555094309 @default.
• W1569087857 cites W1632388334 @default.
• W1569087857 cites W1992615452 @default.
• W1569087857 cites W2005069635 @default.
• W1569087857 cites W2042369318 @default.
• W1569087857 cites W2073623993 @default.
• W1569087857 cites W2079144528 @default.
• W1569087857 cites W2093053044 @default.
• W1569087857 cites W2103702213 @default.
• W1569087857 cites W2115465348 @default.
• W1569087857 cites W2123060958 @default.
• W1569087857 cites W2127843578 @default.
• W1569087857 cites W2135657152 @default.
• W1569087857 cites W2167746331 @default.
• W1569087857 cites W2169166627 @default.
• W1569087857 cites W2328369261 @default.
• W1569087857 cites W4234880996 @default.
• W1569087857 cites W82523143 @default.
• W1569087857 doi "https://doi.org/10.1155/2015/425876" @default.
• W1569087857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4493294" @default.
• W1569087857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26199623" @default.
• W1569087857 hasPublicationYear "2015" @default.
• W1569087857 type Work @default.
• W1569087857 sameAs 1569087857 @default.
• W1569087857 citedByCount "13" @default.
• W1569087857 countsByYear W15690878572016 @default.
• W1569087857 countsByYear W15690878572017 @default.
• W1569087857 countsByYear W15690878572018 @default.
• W1569087857 countsByYear W15690878572019 @default.
• W1569087857 countsByYear W15690878572020 @default.
• W1569087857 countsByYear W15690878572021 @default.
• W1569087857 countsByYear W15690878572023 @default.
• W1569087857 crossrefType "journal-article" @default.
• W1569087857 hasAuthorship W1569087857A5013179673 @default.
• W1569087857 hasAuthorship W1569087857A5014047853 @default.
• W1569087857 hasAuthorship W1569087857A5015023308 @default.
• W1569087857 hasAuthorship W1569087857A5021776984 @default.
• W1569087857 hasAuthorship W1569087857A5032787627 @default.
• W1569087857 hasAuthorship W1569087857A5042401726 @default.
• W1569087857 hasAuthorship W1569087857A5045136564 @default.
• W1569087857 hasAuthorship W1569087857A5056456991 @default.
• W1569087857 hasAuthorship W1569087857A5065692477 @default.
• W1569087857 hasAuthorship W1569087857A5076120991 @default.
• W1569087857 hasAuthorship W1569087857A5078407139 @default.
• W1569087857 hasAuthorship W1569087857A5083668667 @default.
• W1569087857 hasAuthorship W1569087857A5087388222 @default.
• W1569087857 hasBestOaLocation W15690878571 @default.
• W1569087857 hasConcept C11413529 @default.
• W1569087857 hasConcept C121608353 @default.
• W1569087857 hasConcept C126322002 @default.
• W1569087857 hasConcept C143998085 @default.
• W1569087857 hasConcept C2776694085 @default.
• W1569087857 hasConcept C2778119113 @default.
• W1569087857 hasConcept C2778239845 @default.
• W1569087857 hasConcept C2780259306 @default.
• W1569087857 hasConcept C2781451048 @default.
• W1569087857 hasConcept C33923547 @default.
• W1569087857 hasConcept C526805850 @default.
• W1569087857 hasConcept C71924100 @default.
• W1569087857 hasConceptScore W1569087857C11413529 @default.
• W1569087857 hasConceptScore W1569087857C121608353 @default.
• W1569087857 hasConceptScore W1569087857C126322002 @default.
• W1569087857 hasConceptScore W1569087857C143998085 @default.
• W1569087857 hasConceptScore W1569087857C2776694085 @default.
• W1569087857 hasConceptScore W1569087857C2778119113 @default.
• W1569087857 hasConceptScore W1569087857C2778239845 @default.
• W1569087857 hasConceptScore W1569087857C2780259306 @default.
• W1569087857 hasConceptScore W1569087857C2781451048 @default.
• W1569087857 hasConceptScore W1569087857C33923547 @default.
• W1569087857 hasConceptScore W1569087857C526805850 @default.
• W1569087857 hasConceptScore W1569087857C71924100 @default.
• W1569087857 hasLocation W15690878571 @default.
• W1569087857 hasLocation W15690878572 @default.
• W1569087857 hasLocation W15690878573 @default.
• W1569087857 hasLocation W15690878574 @default.
• W1569087857 hasLocation W15690878575 @default.
• W1569087857 hasOpenAccess W1569087857 @default.
• W1569087857 hasPrimaryLocation W15690878571 @default.
• W1569087857 hasRelatedWork W1601338141 @default.
• W1569087857 hasRelatedWork W1777047255 @default.

• next